<DOC>
	<DOCNO>NCT02256553</DOCNO>
	<brief_summary>The purpose study assess safety tolerability MK-3641 ( short ragweed [ Ambrosia artemisiifolia ] extract , SCH 039641 , RAGWITEK速 ) sublingual tablet MK-7243 ( Timothy grass [ Phleum pratense ] extract , SCH 697243 , GRASTEK速 ) sublingual tablet co-administered participant 18 65 year age ragweed- grass polled-induced allergic rhinitis , without conjunctivitis without asthma . The primary endpoint percentage participant experience least one event local swell co-administration MK-3641 MK-7243 sublingual tablet .</brief_summary>
	<brief_title>Safety Study MK-3641 MK-7243 Co-administered Adult Participants With Ragweed Grass Pollen Induced Allergic Rhinitis ( P08607 , MK-3641-006 )</brief_title>
	<detailed_description>Events local swell include pharyngeal edema , laryngeal edema , mouth edema , oropharyngeal swelling , palatal edema , tongue swelling/edema throat tightness .</detailed_description>
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic , Seasonal</mesh_term>
	<criteria>Clinical history physiciandiagnosed ragweed grass polleninduced rhinitis without conjunctivitis &gt; 1 year duration , without asthma Female participant childbearing potential must negative urine pregnancy test Screening Randomization Visits must agree remain abstinent use ( partner use ) one acceptable method birth control within project duration study . Acceptable method birth control : intrauterine device ( IUD ) , diaphragm spermicide , contraceptive sponge , condom , vasectomy , hormonal contraception . Unstable , uncontrolled severe asthma treat longacting beta agonist ( LABAs ) time Screening Received immunosuppressive treatment within 3 month prior Randomization ( except steroid allergic reaction asthma ) History anaphylaxis cardiorespiratory symptom prior immunotherapy , unknown cause , inhalant allergen Diagnosis eosinophilic esophagitis History severe systemic allergic reaction severe local reaction sublingual allergen immunotherapy Female breastfeeding , pregnant intend become pregnant Received another form allergen immunotherapy past month Previously expose MK3641 ( RAGWITEK速 ) sublingual ragweed immunotherapy Previously expose MK7243 ( GRASTEK速 ) sublingual grass immunotherapy Known history allergy , hypersensitivity , intolerance excipient ingredient study drug ( except Ambrosia artemisiifolia and/or Phleum pratense ) , selfinjectable epinephrine Unable comply use selfinjectable epinephrine Used investigational drug within 30 day prior Screening Visit , plan participate another interventional clinical trial duration trial Family member investigational sponsor staff involve trial Participating trial another investigational site .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>